Diabetic Lancing Device Market Research Report- Forecast To 2027

Diabetic lancing device market research report-By type (push button safety lancets, pressure activated safety lancets, side button safety lancets), by gauge (17/18g, 21g, 23g, 25g, 28g,  30g), by penetration depth, by end-user-forecast till 2027

ID: MRFR/MED/4060-HCR | February 2021 | Region: Global | 90 pages

Diabetic lancing device market Scenario:


Diabetes is a global epidemic affecting an estimated 382 million people worldwide. The WHO projects that diabetes will be the 7th leading cause of death by 2030. An estimated 4 million people die annually from the complications associated with diabetes. Therefore, if the current trend associated with the prevalence of diabetes continues over the coming years, the number of diabetic patients across the globe would be tremendous after a decade. Increasing prevalence of diabetes will result in the rising demand for devices and products to monitor and control diabetes, eventually leading to increased consumption of lancets. Thus, the demand for lancets is expected to be enormous in the coming future.

Lancets are one of the widely used alternative device to obtain the blood samples. These devices are receiving global recognition and acceptance due to its several convenient characteristics which gives them an edge over the traditional methods for vein puncture. Some of the important features of the safety lancets are painless vein puncture, easy handling, and safety while using. The major applications of the lancets are HIV screening test, capillary blood micro sampling and cholesterol test, blood group test, coagulation tests, haemoglobin, allergy tests, and many other blood based tests. According to the International Diabetes Federation (IDF), approximately 29.2 million people in the US are estimated suffer from diabetes in 2015. Japan had approximately 7.2 million. in 2015.

Rising prevalence of diabetic population, increasing awareness for blood glucose monitoring device and increased awareness of safety measures in order to avoid the infectious diseases are some of the significant factors of the increased awareness and use of lancets. However, the price erosion is a major issue that is negatively impacting the diabetes management devices. Moreover, significant changes in reimbursement policies in the US for blood glucose monitors, particularly the ongoing impact to the private insurance sector are some of the factors restraining the growth of diabetic lancing device market.

The global diabetic lancing device market is expected to grow at a CAGR of approximately 11.0% during the forecast period 2017-2023.

Research Methodology:

 Research Methodology

Sources: Annual reports, Press release, White paper, and Company presentation

Diabetic Lancing Device Market Segmentation:

The global diabetic lancing devices market is segmented on the basis of type, gauge, penetration depth, and end user.

On the basis of type, the diabetic lancing device market for diabetic lancing devices it is segmented into safety lancets and standard lancets. The safety lancets are further categorized into push-button safety lancets, pressure activated safety lancets, and side button safety lancets. The pen needles is further categorized into standard pen needles and safety pen needles.

On the basis of gauge, the diabetic lancing device market for diabetic lancing devices it is segmented into 17/18g, 21g, 23g, 25g, 28g,  30g, and others.

On the basis of penetration depth, the diabetic lancing devices market is segmented into 0.8 mm to 1.0 mm, 1.1 mm to 1.5 mm, 1.6 mm to 2.0 mm, 2.1 mm to 2.5 mm, 2.5 mm to 3.0 mm, and others.

On the basis of the end users, it is segmented into hospitals & clinics, diagnostic centers & medical institutions, home care & home diagnostics, research & academic laboratories, and others.

Diabetic Lancing Device Market Regional Analysis:

The global diabetic lancing device market consists of countries namely America, Europe, Asia Pacific, and the Middle East and Africa.

Europe is projected to hold the largest share of the global diabetic lancing device market attributed to change in lifestyle, increase in R&D activities for the development of new drugs.  According to the International Diabetes Federation (IDF), in 2015 approximately 59.8 million people had diabetes in Europe. HTL Strefa and Sarstedt are two European companies which have marked their presence on the global level as a major manufacturer of lancets and safety lancets in the world.

The Americas holds a key share in diabetic lancing device market. Moreover, North America dominated the overall market in terms of revenue in 2016. In the U.S., ongoing uncertainty as to the future of the Affordable Care Act and the Trump Administration’s repeal and replace initiative may further impact the market.

Asia Pacific is estimated to be the fastest region to  grow at a high CAGR during the forecast period, led by an increase in government spending on healthcare services in India and China. A large number of lancet manufacturers are from developing Asian countries such as China, India, Japan and Republic of Korea mainly because of the low labour cost and low R&D cost. China being one of the highly populated and technologically advanced developing countries, has a major number of lancets manufacturers. Some of the renowned Chinese Safety Lancet manufacturers are Guangzhou Improve Medical Instruments Co, Huang and KDL China.

The Middle East & Africa diabetic lancing device market is projected to expand during the forecast period, owing to the rise in investments by market players and increase in prevalence of diabetic lancing devices.

Diabetic Lancing Device Market Key Players:

Some of the key players in the global diabetic lancing device market are B. Braun Melsungen AG, Terumo Corporation, Becton Dickinson, Sanofi, F. Hoffmann-La Roche AG, Bayer AG, Novo Nordisk A S, Eli Lilly and Company, Owen Mumford Ltd, Medtronic, Ypsomed Holding AG, Sarstedt AG & Co, Greiner Bio One, Abbott Laboratories, HTL-STREFA S.A, Improve Medical, UltiMed, Inc., Allison Medical, Inc., Artsana S.p.a., VOGT MEDICAL, Perrigo Diabetes Care, MedExel Co., Ltd, ARKRAY Inc., Simple Diagnostics, Stat Medical, Terumo, Trividia Health, and others.

Intended Audience



  • Diabetic Lancing Device Suppliers

  • Diabetic Lancing Device Manufacturers

  • Research and Development (R&D) Companies

  • Medical Research Laboratories

  • Academic Medical Institutes and Universities



Report Scope:
Report Attribute/Metric Details
  Market Size   Significant Value
  CAGR   2017-2023:11.7%
  Base Year   2019
  Forecast Period   2027
  Historical Data   2018
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Type, gauge, penetration depth, and end user
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   B. Braun Melsungen AG, Terumo Corporation, Becton Dickinson, Sanofi, F. Hoffmann-La Roche AG, Bayer AG, Novo Nordisk A S, Eli Lilly and Company, Owen Mumford Ltd, Medtronic, Ypsomed Holding AG, Sarstedt AG & Co, Greiner Bio One, Abbott Laboratories, HTL-STREFA S.A, Improve Medical, UltiMed, Inc., Allison Medical, Inc., Artsana S.p.a., VOGT MEDICAL, Perrigo Diabetes Care, MedExel Co., Ltd, ARKRAY Inc., Simple Diagnostics, Stat Medical, Terumo, Trividia Health, and others
  Key Market Opportunities   Research and Development
  Key Market Drivers

  • Rising prevalence of diabetic population
  • Increasing awareness for blood glucose monitoring device
  • Increased awareness of diabetic


  • Speak to Analyst Ask for Customization

    Frequently Asked Questions (FAQ) :


    diabetic lancing device market is projected to grow at approximately 11.0% CAGR during the assessment period (2017-2023).

    Features of these devices such as painless vein puncture, easy handling, and safety, rising prevalence of diabetic population, and increasing awareness for blood glucose monitoring device, are major tailwinds pushing the growth of the global diabetic lancing device market.

    High price and significant changes in reimbursement policies blood glucose monitors, are major growth impeder for the global diabetic lancing device market.

    Europe holds the largest share in the global diabetic lancing device market, followed by North America and the Asia Pacific, respectively.

    B. Braun Melsungen AG, Becton Dickinson, Terumo Corporation, Sanofi, F. Hoffmann-La Roche AG, Novo Nordisk A S, Bayer AG, Eli Lilly and Company, Medtronic, Owen Mumford Ltd, Ypsomed Holding AG, Greiner Bio One, Sarstedt AG & Co, Abbott Laboratories, Improve Medical, HTL-STREFA S.A, UltiMed, Inc., Artsana S.p.a., Allison Medical, Inc., VOGT MEDICAL, MedExel Co., Ltd, Perrigo Diabetes Care, ARKRAY Inc., Stat Medical, Simple Diagnostics, Terumo, and Trividia Health, are some of the top players operating in the global diabetic lancing device market.

    TABLE OF CONTENT

    Chapter 1. Report Prologue

    Chapter 2. Market Introduction

    2.1 Definition

    2.2 Scope Of The Study

    2.2.1 Research Objective

    2.2.2 Assumptions

    2.2.3 Limitations

    Chapter 3. Research Methodology

    3.1 Introduction

    3.2 Primary Research

    3.3 Secondary Research

    3.4 Market Size Estimation

    Chapter 4. Market Dynamics

    4.1 Drivers

    4.2 Restrains

    4.3 Opportunities

    4.4 Challenges

    4.5 Macroeconomic Indicators

    4.6 Treatment Trends & Assessment

    Chapter 5. Market Factor Analysis

    5.1 Porter’s Five Forces Analysis

    5.1.1 Bargaining Power Of Suppliers

    5.1.2 Bargaining Power Of Buyers

    5.1.3 Threat Of New Entrants

    5.1.4 Threat Of Substitutes

    5.1.5 Intensity Of Rivalry

    5.2 Value Chain Analysis

    5.3 Investment Feasibility Analysis

    5.4 Pricing Analysis

    Chapter 6. Global Diabetic Lancing Device Market, By Type

    6.1 Introduction

    6.2 Standard Lancet

    6.2.1 Market Estimates & Forecast, 2020 – 2023

    6.5 Safety Lancet

    6.5.1 Market Estimates & Forecast, 2020 – 2023

    6.5.2 Push Button Safety Lancets

    6.5.2.1 Market Estimates & Forecast, 2020 – 2023

    6.5.3 Pressure Activated Safety Lancets

    6.5.3.1 Market Estimates & Forecast, 2020 – 2023

    6.5.4 Side Button Safety Lancets

    6.5.4.1 Market Estimates & Forecast, 2020 – 2023

    6.6 Others

    Chapter 7. Global Diabetic Lancing Device Market, By Gauge

    7.1 Introduction

    7.2 17/18G

    7.2.1 Market Estimates & Forecast, 2020 – 2027

    7.3 21G

    7.3.1 Market Estimates & Forecast, 2020 – 2027

    7.4 23G

    7.4.1 Market Estimates & Forecast, 2020 – 2027

    7.5 25G

    7.5.1 Market Estimates & Forecast, 2020 – 2027

    7.6 28G

    7.6.1 Market Estimates & Forecast, 2020 – 2027

    7.7 30G

    7.7.1 Market Estimates & Forecast, 2020 – 2027

    Chapter 8. Global Diabetic Lancing Device Market, By Penetration Depth

    8.1 Introduction

    8.2 0.8 Mm To 1.0 Mm

    8.2.1 Market Estimates & Forecast, 2018 – 2023

    8.3 1.1 Mm To 1.5 Mm

    8.3.1 Market Estimates & Forecast, 2018 – 2023

    8.4 1.6 Mm To 2.0 Mm

    8.4.1 Market Estimates & Forecast, 2018 – 2023

    8.5 2.1 Mm To 2.5 Mm

    8.5.1 Market Estimates & Forecast, 2018 – 2023

    8.6 2.5 Mm To 3.0 Mm

    8.6.1 Market Estimates & Forecast, 2018 – 2023

    8.7 Others

    Chapter 9. Global Diabetic Lancing Device Market, By End User

    9.1 Introduction

    9.2 Hospitals & Clinics

    9.2.1 Market Estimates & Forecast, 2020 – 2027

    9.3 Diagnostic Centers And Pathology Laboratories

    9.3.1 Market Estimates & Forecast, 2020 – 2027

    9.4 Home Diagnostics

    9.4.1 Market Estimates & Forecast, 2020 – 2027

    9.5 Others

    Chapter. 10 Global Diabetic Lancing Device Market, By Region

    10.1 Introduction

    10.2 Americas

    10.2.1 North America

    10.2.1.1 U.S.

    10.2.1.2 Canada

    10.2.2 South America

    10.3 Europe

    10.3.1 Western Europe

    10.3.1.1 Germany

    10.3.1.2 France

    10.3.1.3 Italy

    10.3.1.4 Spain

    10.3.1.5 U.K

    10.3.1.6 Rest Of Western Europe

    10.3.2 Eastern Europe

    10.4 Asia Pacific

    10.4.1 Japan

    10.4.2 China

    10.4.3 India

    10.4.4 Australia

    10.4.5 Republic Of Korea

    10.4.6 Rest Of Asia Pacific

    10.5 The Middle East & Africa

    10.5.1 United Arab Emirates

    10.5.2 Saudi Arabia

    10.5.3 Rest Of The Middle East & Africa

    Chapter 11 Company Landscape

    11.1 Introduction

    11.2 Market Share Analysis

    11.3 Key Development & Strategies

    11.3.1 Key Developments

    Chapter 12 Company Profiles

    12.1 HTL-STREFA S.A.

    12.1.1 Company Overview

    12.1.2 Business Segment Overview

    12.1.3 Financials

    12.1.4 SWOT Analysis

    12.2 Becton, Dickinson And Company

    12.2.1 Company Overview

    12.2.2 Business Segment Overview

    12.2.3 Financial Overview

    12.2.4 Key Developments

    12.2.5 SWOT Analysis

    12.3 Greiner Bio One International GmbH

    12.3.1 Company Overview

    12.3.2 Business Segment Overview

    12.3.3 Financial Overview

    12.3.4 Key Development

    12.3.5 SWOT Analysis

    12.4 Improve Medical Technology Co. Ltd

    12.4.1 Company Overview

    12.4.2 Business Segment Overview

    12.4.3 Financial Overview

    12.4.4 Key Development

    12.4.5 SWOT Analysis

    12.5 Terumo Medical Corporation

    12.5.1 Company Overview

    12.5.2 Business Segment Overview

    12.5.3 Financial Overview

    12.5.4 Key Developments

    12.6 ASAHI POLYSLIDER Inc.

    12.6.1 Company Overview

    12.6.2 Business Segment Overview

    12.6.3 Financial Overview

    12.6.4 Key Developments

    12.7 ARKRAY

    12.7.1 Overview

    12.7.2 Business Segment Overview

    12.7.3 Financials

    12.7.4 Key Developments

    12.7.5 SWOT Analysis

    12.8 Sarstedt AG & Co.

    12.8.1 Company Overview

    12.8.2 Business Segment Overview

    12.8.3 Financial Overview

    12.8.4 Key Development

    12.8.5 SWOT Analysis

    12.9 Abbott Laboratories

    12.9.1 Overview

    12.9.2 Product/Business Segment Overview

    12.9.3 Financial Updates

    12.9.4 Key Developments

    12.10 Smiths Medical

    12.10.1 Company Overview

    12.10.2 Product/Business Segment Overview

    12.10.3 Financial Updates

    12.10.4 Key Development

    12.11 Others

    Chapter 13 MRFR Conclusion

    13.1 Key Findings

    13.1.1 From CEO’s View Point

    13.1.2 Unmet Needs Of The Market

    13.2 Key Companies To Watch

    13.3 Prediction Of Pharmaceutical Industry

    Chapter 14 Appendix

    LIST OF TABLES

    Table 1 Diabetic Lancing Device Industry Synopsis, 2020 – 2027

    Table 2 Diabetic Lancing Device Market Estimates And Forecast, 2020 – 2027, (USD Million)

    Table 3 Diabetic Lancing Device Market By Region, 2020 – 2027, (USD Million)

    Table 4 Diabetic Lancing Device Market By Type, 2020 – 2027, (USD Million)

    Table 5 Diabetic Lancing Device Market By Gauge, 2020 – 2027, (USD Million)

    Table 6 Diabetic Lancing Device Market By Penetration Depth, 2020 – 2027, (USD Million)

    Table 7 Diabetic Lancing Device Market By End Users, 2020 – 2027, (USD Million)

    Table 8 North America Diabetic Lancing Device Market By Type, 2020 – 2027, (USD Million)

    Table 9 North America Diabetic Lancing Device Market By Gauge, 2020 – 2027, (USD Million)

    Table 12 North America Diabetic Lancing Device Market By Penetration Depth, 2020 – 2027, (USD Million)

    Table 11 North America Diabetic Lancing Device Market By End User, 2020 – 2027, (USD Million)

    Table 12 US Diabetic Lancing Device Market By Type, 2020 – 2027, (USD Million)

    Table 13 US Diabetic Lancing Device Market By Gauge, 2020 – 2027, (USD Million)

    Table 14 US Diabetic Lancing Device Market By Penetration Depth, 2020 – 2027, (USD Million)

    Table 15 US Diabetic Lancing Device Market By End User, 2020 – 2027, (USD Million)

    Table 16 Canada Diabetic Lancing Device Market By Type, 2020 – 2027, (USD Million)

    Table 17 Canada Diabetic Lancing Device Market By Gauge, 2020 – 2027, (USD Million)

    Table 18 Canada Diabetic Lancing Device Market By Penetration Depth, 2020 – 2027, (USD Million)

    Table 19 Canada Diabetic Lancing Device Market By End User, 2020 – 2027, (USD Million)

    Table 20 South America Diabetic Lancing Device Market By Type, 2020 – 2027, (USD Million)

    Table 21 South America Diabetic Lancing Device Market By Gauge, 2020 – 2027, (USD Million)

    Table 22 South America Diabetic Lancing Device Market By Penetration Depth, 2020 – 2027, (USD Million)

    Table 23 South America Diabetic Lancing Device Market By End User, 2020 – 2027, (USD Million)

    Table 24 Europe Diabetic Lancing Device Market By Type, 2020 – 2027, (USD Million)

    Table 25 Europe Diabetic Lancing Device Market By Gauge, 2020 – 2027, (USD Million)

    Table 26 Europe Diabetic Lancing Device Market By Penetration Depth, 2020 – 2027, (USD Million)

    Table 27 Europe Diabetic Lancing Device Market By End User, 2020 – 2027, (USD Million)

    Table 28 Western Europe Diabetic Lancing Device Market By Type, 2020 – 2027, (USD Million)

    Table 29 Western Europe Diabetic Lancing Device Market By Gauge, 2020 – 2027, (USD Million)

    Table 30 Western Europe Diabetic Lancing Device Market By Penetration Depth, 2020 – 2027, (USD Million)

    Table 31 Western Europe Diabetic Lancing Device Market By End User, 2020 – 2027, (USD Million)

    Table 32 Eastern Europe Diabetic Lancing Device Market By Type, 2020 – 2027, (USD Million)

    Table 33 Eastern Europe Diabetic Lancing Device Market By Gauge, 2020 – 2027, (USD Million)

    Table 34 Eastern Europe Diabetic Lancing Device Market By Penetration Depth, 2020 – 2027, (USD Million)

    Table 35 Eastern Europe Diabetic Lancing Device Market By End User, 2020 – 2027, (USD Million)

    Table 36 Asia Pacific Diabetic Lancing Device Market By Type, 2020 – 2027, (USD Million)

    Table 37 Asia Pacific Diabetic Lancing Device Market By Gauge, 2020 – 2027, (USD Million)

    Table 38 Asia Pacific Diabetic Lancing Device Market By Penetration Depth, 2020 – 2027, (USD Million)

    Table 39 Asia Pacific Diabetic Lancing Device Market By End User, 2020 – 2027, (USD Million)

    Table 40 The Middle East & Africa Diabetic Lancing Device Market By Type, 2020 – 2027, (USD Million)

    Table 41 The Middle East & Africa Diabetic Lancing Device Market By Gauge, 2020 – 2027, (USD Million)

    Table 42 The Middle East & Africa Diabetic Lancing Device Market By Penetration Depth, 2020 – 2027, (USD Million)

    Table 43 The Middle East & Africa Diabetic Lancing Device Market By End User, 2020 – 2027, (USD Million)

    LIST OF FIGURES

    Figure 1 Research Process

    Figure 2 Segmentation For Diabetic Lancing Device Market

    Figure 3 Segmentation Market Dynamics For Diabetic Lancing Device Market

    Figure 4 Global Diabetic Lancing Device Market Share, By Type 2020

    Figure 5 Global Diabetic Lancing Device Market Share, By Gauge 2020

    Figure 6 Global Diabetic Lancing Device Market Share, By Penetration Depth, 2020

    Figure 7 Global Diabetic Lancing Device Market Share, By End Users, 2020

    Figure 9 Global Diabetic Lancing Device Market Share, By Region, 2020

    Figure 12 North America Diabetic Lancing Device Market Share, By Country, 2020

    Figure 11 Europe Diabetic Lancing Device Market Share, By Country, 2020

    Figure 12 Asia Pacific Diabetic Lancing Device Market Share, By Country, 2020

    Figure 13 The Middle East & Africa Diabetic Lancing Device Market Share, By Country, 2020

    Figure 14 Global Diabetic Lancing Device Market: Company Share Analysis, 2020 (%)

    Figure 15 HTL-STREFA S.A.: Key Financials

    Figure 16 HTL-STREFA S.A.: Segmental Revenue

    Figure 17 HTL-STREFA S.A.: Geographical Revenue

    Figure 18 Becton, Dickinson And Company: Key Financials

    Figure 19 Becton, Dickinson And Company: Segmental Revenue

    Figure 20 Becton, Dickinson And Company: Geographical Revenue

    Figure 21 Greiner Bio One International GmbH: Key Financials

    Figure 22 Greiner Bio One International GmbH: Segmental Revenue

    Figure 23 Greiner Bio One International GmbH: Geographical Revenue

    Figure 24 Improve Medical Technology Co. Ltd: Key Financials

    Figure 25 Improve Medical Technology Co. Ltd: Segmental Revenue

    Figure 26 Improve Medical Technology Co. Ltd: Geographical Revenue

    Figure 27 Terumo Medical Corporation: Key Financials

    Figure 28 Terumo Medical Corporation: Segmental Revenue

    Figure 29 Terumo Medical Corporation: Geographical Revenue

    Figure 30 ASAHI POLYSLIDER Inc.: Key Financials

    Figure 31 ASAHI POLYSLIDER Inc.: Segmental Revenue

    Figure 32 ASAHI POLYSLIDER Inc.: Geographical Revenue

    Figure 33 ARKRAY: Key Financials

    Figure 34 ARKRAY: Segmental Revenue

    Figure 35 ARKRAY: Geographical Revenue